Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic User Fees: FDA Wants To Reduce The Number Of Amendments Per Application

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency proposes a priority system for ANDA amendments to cut down on "development on the clock"; draft goals letter to be prepared.

You may also be interested in...

Generic User Fee Talks: Performance Metrics For Early Years Still Unresolved

Industry and FDA appear largely in agreement on goals for the generic drug user fee program after it gets off the ground, but are stuck on how to determine agency performance in its early years.

Pre-NDA Work Takes Added Importance As PDUFA V Stretches Review Cycle

PDUFA V: FDA Application Completeness Crackdown Continues

FDA remains firm in its push for application completeness in PDUFA V, despite its willingness to add two new review cycle meetings with sponsors.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts